Sakthiraj Subramanian, MD
Internal Medicine · Willow Park, TXNPI 1669676326
Payments from drug & device makers
Across 247 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$699
- AstraZeneca$614
- Boehringer Ingelheim$306
- Lilly USA, LLC$263
- Sanofi-aventis U.S. LLC$203
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,844100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,133 |
| AbbVie(2 entities) | 31 | $699 |
| AstraZeneca | 23 | $614 |
| Boehringer Ingelheim | 15 | $306 |
| Lilly USA, LLC | 17 | $263 |
| Sanofi-aventis U.S. LLC | 13 | $203 |
| Pfizer | 14 | $193 |
| Dexcom, Inc. | 1 | $150 |
| GSK | 9 | $140 |
| Daiichi Sankyo Inc. | 1 | $132 |
| Phathom Pharmaceuticals, Inc. | 2 | $112 |
| Aimmune Therapeutics, Inc. | 1 | $89 |
| Amgen | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $60 |
| Johnson & Johnson | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Merck | 4 | $48 |
| Astellas Pharma US Inc | 3 | $47 |
| Bayer | 3 | $44 |
| Nalpropion Pharmaceuticals LLC | 3 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 2 | $27 |
| Eisai Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Biogen | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$227
- FARXIGA$226
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
- INJECTAFER$132
- Skyrizi$119
- DALVANCE$108
How this compares
$4,862 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 227 | $341,060 |
| MounjaroTirzepatide | 121 | $177,833 |
| JardianceEmpagliflozin | 138 | $165,948 |
| TrulicityDulaglutide | 57 | $95,116 |
| EliquisApixaban | 71 | $83,848 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $81,133 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $62,224 |
| RybelsusSemaglutide | 30 | $51,783 |
| FarxigaDapagliflozin Propanediol | 32 | $44,508 |
| XareltoRivaroxaban | 28 | $38,220 |
| VascepaIcosapent Ethyl | 34 | $25,533 |
| MyrbetriqMirabegron | 35 | $22,336 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $21,503 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $20,758 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $17,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,133 | $410,689269 claims |
| Lilly USA, LLCMounjaro, Trulicity | $263 | $272,949178 claims |
| Boehringer IngelheimJardiance | $306 | $165,948138 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $140 | $102,636136 claims |
| PfizerEliquis, Premarin | $193 | $87,74582 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $203 | $62,22458 claims |
| AstraZenecaFarxiga, Symbicort | $614 | $50,53146 claims |
| Johnson & JohnsonXarelto | $60 | $38,22028 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $22,33635 claims |
| AbbVieLinzess | $699 | $11,00816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Willow Park
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.